» Articles » PMID: 27978984

Translational PK/PD Modeling to Increase Probability of Success in Drug Discovery and Early Development

Overview
Publisher Elsevier
Date 2016 Dec 17
PMID 27978984
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

In this review we present ways in which translational PK/PD modeling can address opportunities to enhance probability of success in drug discovery and early development. This is achieved by impacting efficacy and safety-driven attrition rates, through increased focus on the quantitative understanding and modeling of translational PK/PD. Application of the proposed principles early in the discovery and development phases is anticipated to bolster confidence of successfully evaluating proof of mechanism in humans and ultimately improve Phase II success. The present review is centered on the application of predictive modeling and simulation approaches during drug discovery and early development, and more specifically of mechanism-based PK/PD modeling. Case studies are presented, focused on the relevance of M&S contributions to real-world questions and the impact on decision making.

Citing Articles

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.

Alasmari M, Albusaysi S, Elhefnawy M, Ali A, Altigani K, Almoslem M Saudi Pharm J. 2024; 32(12):102207.

PMID: 39697476 PMC: 11653594. DOI: 10.1016/j.jsps.2024.102207.


Model Systems in Endometriosis Research: Translation, Translation, Translation!.

Groothuis P Front Reprod Health. 2022; 3:809366.

PMID: 36304048 PMC: 9580766. DOI: 10.3389/frph.2021.809366.


A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues.

Lohasz C, Loretan J, Sterker D, Gorlach E, Renggli K, Argast P Front Pharmacol. 2022; 12:785851.

PMID: 35342386 PMC: 8954798. DOI: 10.3389/fphar.2021.785851.


Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs.

Walz A, Van De Vyver A, Yu L, Birtwistle M, Krogan N, Bouhaddou M Pharmacol Ther. 2022; 235:108162.

PMID: 35189161 PMC: 9292061. DOI: 10.1016/j.pharmthera.2022.108162.


Safety pharmacology during the COVID pandemic.

Pugsley M, Koshman Y, de Korte T, Authier S, Curtis M J Pharmacol Toxicol Methods. 2021; 111:107089.

PMID: 34182120 PMC: 8233455. DOI: 10.1016/j.vascn.2021.107089.